Key Takeaways:
- Hengrui Pharma’s SHR-A1811 granted Breakthrough Therapy status in China.
- The designation is for treating a specific type of HER2-positive breast cancer.
- This marks the 11th such designation for the drug, speeding its review process.
Back
Hengrui Pharma Drug Gets 11th Breakthrough Tag for Breast Cancer
Hengrui Pharmaceuticals (01276.HK) announced its injectable drug SHR-A1811 received Breakthrough Therapy Designation in China for what is now its 11th proposed indication.
The designation, granted by the Center for Drug Evaluation of the National Medical Products Administration, is for treating HER2-positive breast cancer, the company said in a statement.
The proposed indication covers the drug's use in combination with pertuzumab for patients with recurrent or metastatic HER2-positive breast cancer who have not previously received anti-HER2 therapy. The Breakthrough Therapy Designation is designed to expedite the development and review of innovative drugs for serious conditions.
Gaining this status can significantly shorten the timeline for SHR-A1811 to reach the market, de-risking a key asset in Hengrui's oncology pipeline. The accelerated path to potential commercialization for this 11th indication strengthens the drug's profile and could positively impact investor outlook on the company's valuation.
The repeated receipt of Breakthrough Therapy Designations for SHR-A1811 across multiple cancer types highlights its potential as a versatile treatment. Investors will now watch for the initiation of Phase three trials and subsequent data readouts, which will be critical catalysts for the drug's final approval and commercial launch.
This article is for informational purposes only and does not constitute investment advice.
© 2026 Edgen Powered by